Lineage Cell Therapeutics, Inc. (LCTX) Stock Forecast
LCTX analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.43 / 5 from 7 analysts
- Price target
- $5.50 average of analyst targets
- Upside to target
- +461.2% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.02
- 52-week range
- $0.90 – $1.96
LCTX analyst ratings
7 analystsNumber of analysts at each rating.
LCTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
LCTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.04 | −$0.04 | −$0.03 | −$0.13 | +73.1% | 4 |
| Current fiscal year (2026) | −$0.07 | −$0.13 | $0.04 | −$0.22 | +70.0% | 4 |
| Next fiscal year (2027) | −$0.14 | −$0.16 | −$0.12 | −$0.07 | −111.5% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
LCTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $2.0M | $0 | $7.5M | −46.0% | 7 |
| Current fiscal year (2026) | $15.2M | $2.8M | $36.4M | +4.4% | 7 |
| Next fiscal year (2027) | $16.8M | $0 | $74.9M | +10.8% | 7 |
LCTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
LCTX revenue: reported and forecast
LCTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.03 | −$0.03 | −$0.04 | −$0.04 | −$0.04 | +16.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$0.07 | −$0.07 | −$0.06 | −$0.06 | −$0.07 | −1.5% | 0 up · 0 down |
| Next fiscal year (2027) | −$0.09 | −$0.09 | −$0.10 | −$0.10 | −$0.14 | +52.8% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
LCTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; LCTX beat in 8 of 12.
What analysts expect from LCTX
7 analysts cover Lineage Cell Therapeutics; their consensus rating is buy (4.43 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.50, 461.2% above the latest close of $0.98. Analysts expect earnings of −$0.07 per share for 2026, +70.0% from a year earlier. For 2027 the average estimate is −$0.14 per share on revenue of $16.8 million. Lineage Cell Therapeutics beat the EPS estimate in 8 of the last 12 quarters.
Related: LCTX income statement, LCTX key metrics, LCTX chart. See the LCTX stock overview for the latest quote and news.
LCTX forecast FAQ
What is Lineage Cell Therapeutics's price target?
The average analyst price target for Lineage Cell Therapeutics is $5.50, 461.2% above the latest close of $0.98.
Is Lineage Cell Therapeutics a buy, hold or sell?
Of 7 analysts covering Lineage Cell Therapeutics, 4 rate it a strong buy, 2 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Lineage Cell Therapeutics's EPS forecast?
Analysts forecast −$0.07 per share for 2026 (range −$0.13 to $0.04); for 2027 the estimate is −$0.14.
What is Lineage Cell Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $15.2 million, growth of 4.4%; for 2027 it is $16.8 million.
When does Lineage Cell Therapeutics report earnings?
Lineage Cell Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.02.
Does Lineage Cell Therapeutics usually beat earnings estimates?
Lineage Cell Therapeutics reported EPS at or above the analyst estimate in 8 of the last 12 quarters.